Post by HTGF | High-Tech Gründerfonds

✨ Gilead Sciences to Acquire HTGF-Backed Biotech Tubulis GmbH for up to $5 Billion Gilead will acquire all of the outstanding equity of Tubulis for $3.15 billion in upfront cash consideration on a cash-free, debt-free basis and up to $1.85 billion in contingent milestone payments. HTGF | High-Tech Gründerfonds backed Tubulis from its pre-founding phase to clinical development. We co-led the Series A in 2020 and supported Tubulis’ growth as a trusted partner and investor in follow-on rounds including the largest-ever HTGF Opportunity Growth Fund investment to date. The transaction marks: 🔹HTGF's highest-valued exit to date 🔹The third unicorn exit in HTGF's life sciences portfolio The acquisition significantly expands Gilead’s ADC capabilities by adding next-generation assets and platforms designed to more selectively deliver diverse payloads to tumors and maximize patient benefit. 💬 Dr. Dominik Schumacher, CEO and Co-Founder of Tubulis: “HTGF was one of our earliest investors and supported us in shaping Tubulis during its formative years. Their continued partnership through all phases reflects the shared conviction in our mission and trusted relationship we have built. Investors who engage at such early stages and remain committed long-term are essential for the German and European biotech ecosystem.” 💬 Dr. Frank Hensel, Principal at HTGF: “We started our relationship with Tubulis when the renaissance of the ADC-field had just started and always believed in the potential of the Tubulis platform. Today's acquisition by Gilead validates both the platform's strength and the team's strong execution.” 💬 Dr. Bernd Goergen, Partner at HTGF: “Considering Tubulis' fantastic development leading to this acquisition, our claim 'We believe in tech. We invest in people.' has received the nicest validation possible. Thank you for letting us be part of this journey.” 💬 Dr. Achim Plum, Managing Director at HTGF: “Tubulis is a prime example of our investment philosophy: building strong partnerships with exceptional founders and staying with them for the long run. We believe stories like Tubulis inspire founders across Europe to pursue bold scientific visions. It also gives us strong momentum as we prepare HTGF V, our next seed fund generation.” We are incredibly proud of what the Tubulis Team has achieved. Congratulations to everyone involved! 🎉 Find all details in the press release in the comments. 👇